All Stories

  1. Gray Matter Volume Abnormalities and the Association with the Trajectory of Symptoms and Functioning in Individuals at Clinical High Risk of Psychosis
  2. Multimodal biological profiles of symptom-based subgroups in recent-onset psychosis
  3. Association between non-adherence to fish oil or placebo as a risk factor of transition to psychosis in ultra-high-risk individuals in the NEURAPRO study
  4. Brain Fractal Dimension and Machine Learning can predict first-episode psychosis and risk for transition to psychosis
  5. From Snapshots to Stable Outcomes: Resting-State Functional Magnetic Resonance Imaging–Based Prognosis of Functioning in Patients With Psychosis Risk or Recent-Onset Depression
  6. Editorial AWMH June 2025
  7. Exploring the predictive value of structural covariance networks for the diagnosis of schizophrenia
  8. Women's reproductive mental health: currently available evidence and future directions for research, clinical practice and health policy
  9. Cognitive Trajectories in the Nine Months following Recent-Onset Major Depressive Disorder
  10. Refining Schizophrenia Risk Assessment: Machine Learning Delineates a Brain Signature of Cognitive Basic Symptoms
  11. Individualized pretest risk estimates to guide treatment decisions in patients with clinical high risk for psychotic disorders
  12. Clinical prediction model for transition to psychosis in individuals meeting At Risk Mental State criteria
  13. Association between Adverse Childhood Experiences and long-term outcomes in people at Clinical High-Risk for Psychosis
  14. Editorial 1/25
  15. Differential associations between cytokine and complement proteins in the clinical high risk and first episode stages of psychosis: Blood based investigation across three international studies of psychosis: NEURAPRO, STEP and OPTiMiSE
  16. Active treatment of affective disturbances may improve functional outcomes in patients in the early state of psychosis: Results of the PRONIA study
  17. Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk Individuals
  18. The effects of recent stressful life events on outcomes in individuals at clinical high risk for psychosis: results from the longitudinal EU-GEI high-risk study
  19. Parsing heterogeneity in global and local white matter integrity at different stages across the psychosis continuum
  20. Breaking barriers in the career development of women in academic psychiatry
  21. Do Cognitive Subtypes Exist in People at Clinical High Risk for Psychosis? Results From the EU-GEI Study
  22. Parsing heterogeneity in global and local white matter integrity at different stages across the psychosis continuum
  23. The role of gender as a barrier to the professional development of psychiatrists
  24. Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis
  25. Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis
  26. Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis
  27. Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
  28. Dysregulated Lipid Metabolism Precedes Onset of Psychosis
  29. Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression
  30. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
  31. The association between migrant status and transition in an ultra-high risk for psychosis population
  32. Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
  33. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people
  34. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis
  35. EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients
  36. Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study
  37. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis
  38. Editorial
  39. Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis
  40. EEG microstates as biomarker for psychosis in ultra-high-risk patients
  41. Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population
  42. Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  43. Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?
  44. Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders
  45. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial
  46. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis
  47. Dysregulated lipid metabolism precedes onset of psychosis in people at clinical high risk
  48. Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis
  49. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes
  50. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis
  51. Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study
  52. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial
  53. Individualized prediction of psychosis in subjects with an at-risk mental state
  54. Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis
  55. An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium
  56. Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis
  57. Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review
  58. Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk
  59. Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach
  60. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  61. Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study
  62. Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis
  63. No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis
  64. Correction
  65. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
  66. Estrogens and SERMS as adjunctive treatments for schizophrenia
  67. O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY
  68. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial
  69. Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status
  70. Bride price payment and women’s autonomy: Findings from qualitative interviews from Nigeria
  71. WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women
  72. Dynamic prediction of transition to psychosis using joint modelling
  73. Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis
  74. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
  75. Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression
  76. The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis
  77. Sexually dimorphic subcortical brain volumes in emerging psychosis
  78. Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?
  79. Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis
  80. Clinical trajectories in the ultra-high risk for psychosis population
  81. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients
  82. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
  83. Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at-risk mental state and first-episode psychosis
  84. Disorganized Gyrification Network Properties During the Transition to Psychosis
  85. Sex and gender differences in schizophrenic psychoses—a critical review
  86. Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling
  87. The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding
  88. T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY
  89. O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
  90. S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING
  91. T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY
  92. T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION
  93. Abnormal brain connectivity during error-monitoring in the psychosis high-risk state
  94. Letter from the Editor-in-Chief
  95. Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume
  96. The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis-Factor structure, reliability, and predictive validity
  97. Gender differences in first self‐perceived signs and symptoms in patients with an at‐risk mental state and first‐episode psychosis
  98. Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women
  99. Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients
  100. Age-related brain structural alterations as an intermediate phenotype of psychosis
  101. Duration of untreated psychosis/illness and brain volume changes in early psychosis
  102. Patient-Identified Priorities Leading to Attempted Suicide
  103. Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences
  104. Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state
  105. Prediction of conversion to psychosis in individuals with an at-risk mental state
  106. Outcome of individuals “not at risk of psychosis” and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP)
  107. Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis
  108. Estradiol Production Suppressed by Prolactin in at-risk Mental State and First Episode Psychosis Female Patients? Preliminary Results
  109. Long-term rates of remission and late psychotic transition of individuals at risk for psychosis
  110. Stigma in early detection of psychosis: Subjective experiences of those concerned
  111. The Current European Status
  112. The Relationship Between Negative Symptoms and Cognitive Functioning in Patients with an at Risk Mental State for Psychosis
  113. Verbal Learning and Memory in At-risk Mental State and First Episode Psychosis Patients and Their Correlates to Brain Structural Alterations
  114. Working Together for Early Detection of Psychosis
  115. Autonomy and Reproductive Rights of Married Ikwerre Women in Rivers State, Nigeria
  116. Letter from the Editor-in-Chief
  117. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting
  118. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
  119. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses
  120. Sex and gender differences in mental disorders
  121. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis
  122. Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms
  123. Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders
  124. Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis
  125. Pourquoi et comment soigner plus précocement les troubles psychotiques ?
  126. Alterations in the hippocampus and thalamus in individuals at high risk for psychosis
  127. Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis
  128. Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms
  129. Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis
  130. Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study
  131. High time for a paradigm shift in psychiatry
  132. Neural oscillations in antipsychotic-naïve patients with a first psychotic episode
  133. Longitudinal determinants of client treatment satisfaction in an intensive first-episode psychosis treatment programme
  134. The role of vulnerability factors in individuals with an at-risk mental state of psychosis
  135. Early psychosis in young women
  136. Sex and gender differences in schizophrenic psychoses
  137. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk
  138. Appropriateness of Care and Joint Decision-Making Strategies
  139. Menopause and Mental Health
  140. The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
  141. Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients
  142. Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment
  143. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction
  144. Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender
  145. Early detection of psychosis: helpful or stigmatizing experience? A qualitative study
  146. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders
  147. Modulation of motivational salience processing during the early stages of psychosis
  148. Depression in der Peripartalzeit – Diagnostik, Therapie und Prophylaxe
  149. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers
  150. EPA guidance on the early detection of clinical high risk states of psychoses
  151. EPA guidance on the early intervention in clinical high risk states of psychoses
  152. Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution
  153. Das Basler Interview für Psychosen (BIP): Struktur, Reliabilität und Validität
  154. Perinatal mental health service provision in Switzerland and in the UK
  155. Autism Spectrum Disorders
  156. Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments
  157. Sex Differences in Cognitive Functioning in At-Risk Mental State for Psychosis, First Episode Psychosis and Healthy Control Subjects
  158. Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing
  159. Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication
  160. Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology
  161. Früherkennung und Frühintervention bei beginnenden Psychosen
  162. Comorbidity of Mental and Physical Disorders
  163. Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity
  164. Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis
  165. Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses
  166. Evidence for an agitated–aggressive syndrome predating the onset of psychosis
  167. Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state
  168. Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers
  169. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  170. Effects of heroin
  171. Poster #S162 DEFICITS IN FINE MOTOR SKILLS IN EMERGING PSYCHOSIS
  172. Poster #M222 PSYCHOSIS EARLY DETECTION: HELPFUL OR STIGMATIZING EXPERIENCE? A QUALITATIVE PILOT STUDY
  173. Poster #S147 EYE MOVEMENT ABNORMALITIES IN ADULTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  174. HELP-SEEKING AND PATHWAYS TO CARE IN THE EARLY STAGES OF PSYCHOSIS: RESULTS FROM THE FEPSY STUDY
  175. Poster #T189 DEVIANT NEURAL OSCILLATIONS AND LAGGED PHASE SYNCHRONICITY IN PATIENTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  176. Poster #M40 THE RELATION OF ABNORMAL BRAIN CONNECTIVITY AND PSYCHIATRIC SYMPTOM EXPRESSION IN SUBJECTS AT HIGH-RISK FOR PSYCHOSIS
  177. Poster #T180 THE COURSE OF COGNITIVE FUNCTIONING IN CLINICAL HIGH RISK AND FIRST-EPISODE PSYCHOSIS INDIVIDUALS
  178. Poster #S109 THE BASEL INTERVIEW FOR PSYCHOSIS: STRUCTURE, RELIABILITY AND VALIDITY
  179. Poster #T220 TRANSITION AND PSYCHOSIS RELATED HEMODYNAMIC CORRELATES OF MOTIVATIONAL SALIENCE PROCESSING
  180. THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?
  181. Schmidt a psychosis
  182. Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis
  183. The attenuated psychosis syndrome in DSM-5
  184. Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?
  185. Violence against women and mental health
  186. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis
  187. Boothe B, Riecher-Rössler A (Hrsg) (2013) Frauen in Psychotherapie. Grundlagen – Störungsbilder – Behandlungskonzepte
  188. Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders
  189. Comentario de libro
  190. Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis
  191. S.10.03 Hyperprolactinemia in drug-naïve first-episode patients: data from EUFEST
  192. P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis
  193. P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin
  194. Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study
  195. Brain Connectivity Abnormalities Predating the Onset of Psychosis
  196. Sollen junge Menschen mit Psychoserisikosyndrom behandelt werden?
  197. Häusliche Gewalt bei Frauen einer Kriseninterventionspopulation - Formen der Gewalt und Risikofaktoren
  198. Cannabis use and cognitive functions in at-risk mental state and first episode psychosis
  199. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study
  200. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
  201. Suicide attempts in the county of Basel: results from the WHO/EURO Multicentre Study on Suicidal Behaviour
  202. Vorhersage von Psychosen durch stufenweise Mehrebenenabklärung - Das Basler FePsy(Früherkennung von Psychosen)-Projekt
  203. Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control
  204. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis
  205. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis
  206. Acute effects of heroin on emotions in heroin‐dependent patients
  207. Duration of untreated psychosis and cognitive functioning
  208. Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response
  209. Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial
  210. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial
  211. Violence against Women and Mental Health
  212. Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study
  213. The Psychosis High-Risk State
  214. 2710 – Gender Differences in the Psychopathology of Emerging Psychosis
  215. Do Subjects at Clinical High Risk for Psychosis Differ from those with a Genetic High Risk? - A Systematic Review of Structural and Functional Brain Abnormalities
  216. Help-seeking and pathways to care in the early stages of psychosis
  217. Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study
  218. Can cognitive deficits facilitate differential diagnosis between at‐risk mental state for psychosis and depressive disorders?
  219. Kann Cannabis das Risiko für schizophrene Psychosen erhöhen?
  220. Whither the Attenuated Psychosis Syndrome?
  221. P.2.a.018 Actigraphically measured poor sleep is related to cortisol awakening response and parenting stress in postpartum depression
  222. P.1.e.014 Hippocampal volume in individuals with an at-risk mental state: a longitudinal magnetic resonance imaging analysis
  223. Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies
  224. Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition
  225. Group Treatment for Depression in Mothers of Young Children Compared to Standard Individual Therapy
  226. Priorities for research in child maltreatment, intimate partner violence and resilience to violence exposures: results of an international Delphi consensus development process
  227. Cost of attempted suicide: a retrospective study of extent and associated factors
  228. Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS
  229. Poster #43 NEGATIVE SYMPTOMS IN THE EARLY STAGES OF PSYCHOSIS ARE ASSOCIATED WITH CHANGES IN THE CINGULATE
  230. Poster #52 DURATION OF UNTREATED ILLNESS/PSYCHOSIS AND COGNITIVE FUNCTIONING
  231. Poster #236 LONGITUDINAL CHANGES OF PSYCHOPATHOLOGICAL SYMPTOMS IN AT-RISK MENTAL STATE (ARMS) INDIVIDUALS WITHOUT TRANSITION TO PSYCHOSIS
  232. Poster #56 INSULAR VOLUME ABNORMALITIES ASSOCIATED WITH DIFFERENT TRANSITION PROBABILITIES TO PSYCHOSIS – A VOXEL-BASED MORPHOMETRY STUDY
  233. Poster #51 CANNABIS USE AND BRAIN STRUCTURAL ALTERATIONS OF CINGULATE CORTEX AND HIPPOCAMPUS IN FIRST EPISODE PSYCHOSIS PATIENTS AND AT RISK MENTAL STATE SUBJECTS
  234. Poster #127 DO NEUROLOGICAL SOFT SIGNS IN AT-RISK MENTAL STATE INDIVIDUALS PREDICT TRANSITION TO FIRST EPISODE PSYCHOSIS?
  235. First self‐perceived signs and symptoms in emerging psychosis compared with depression
  236. Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study
  237. Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?
  238. Cingulate Volume Abnormalities in Emerging Psychosis
  239. Attempted Suicide in Immigrants from Turkey: A Comparison with Swiss Suicide Attempters
  240. The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence
  241. Themenschwerpunkt „Women‘s Mental Health“
  242. Depression und Psychose in der Menopause - kann eine Hormontherapie hilfreich sein?
  243. Insular volume abnormalities associated with different transition probabilities to psychosis
  244. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective
  245. Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study
  246. Different duration of at‐risk mental state associated with neurofunctional abnormalities. A multimodal imaging study
  247. Missbrauch in therapeutischen Beziehungen
  248. Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)
  249. Sexual Dysfunction in First-Episode Schizophrenia Patients
  250. Neuroanatomical Abnormalities That Predate the Onset of Psychosis
  251. Patienten mit intensivpflichtigen medikamentösen Suizidversuchen – Risikoprofil und Verlauf
  252. A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression
  253. Stress reactivity in patients with drug dependence and personality disorders
  254. Missbrauch in therapeutischen Beziehungen
  255. 5 Psychosen in Schwangerschaft und Stillzeit
  256. 10 Psychopharmakotherapie in Schwangerschaft und Stillzeit
  257. 8 Depressionen in der Postpartalzeit
  258. 1 Depressionen in der Schwangerschaft
  259. 13 Lichttherapie bei Depressionen in der Schwangerschaft
  260. 12 Gruppentherapie für Mütter mit Depressionen
  261. Pituitary volume increase during emerging psychosis
  262. Depression in der Schwangerschaft
  263. Depression in der frühen Mutterschaft
  264. EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis
  265. The Self-screen-Prodrome as a short screening tool for pre-psychotic states
  266. Hyperprolactinaemia in early psychosis—not only due to antipsychotics
  267. Domestic violence against women: Definitions, epidemiology, risk factors and consequences
  268. Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis
  269. Neural effects of heroin — Relation to anxiety stress
  270. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study
  271. Prospects for the classification of mental disorders in women
  272. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)
  273. QEEG SPECTRAL POWER AND NEGATIVE SYMPTOMS IN THE DETECTION OF BEGINNING PSYCHOSIS
  274. VERBAL EPISODIC MEMORY IN FIRST EPISODE AND AT RISK MENTAL STATE FOR PSYCHOSIS PATIENTS COMPARED TO DEPRESSIVE PATIENTS AND HEALTHY CONTROLS
  275. COMPARISON OF CLINICAL ROUTINE EEG AND QUANTITATIVE EEG IN FIRST EPISODE OF PSYCHOSIS AND AT-RISK MENTAL STATE INDIVIDUALS
  276. Antipsychotic Drug Treatment in First-Episode Psychosis
  277. P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis
  278. Schizophrenia in women
  279. Estrogens and Gonadal Function in Schizophrenia and Related Psychoses
  280. S25-03 - At Risk Mental State for Psychosis: Clinical Features and Natural Course
  281. PW01-21 - Poor Sleep is Related to Parenting Stress and Impaired Postpartum Bonding in Depressed Mothers
  282. Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters
  283. Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up
  284. Prediction of Caseness for Mental Pathology in Swiss Conscripts: The Self-Screen Prodrome
  285. Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study
  286. Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia
  287. 04. Differential correlation of EEG power and negative symptoms in patients with and without transition to psychosis
  288. 06. QEEG spectral power density changes in the early course of schizophrenia
  289. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
  290. Schwangerschaftsdepression und deren Behandlung
  291. Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?
  292. The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review
  293. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
  294. Intervention in Individuals at Ultra-High Risk for Psychosis
  295. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
  296. Correction
  297. The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?
  298. EEG: a helpful tool in the prediction of psychosis
  299. „Selbstscreen-Prodrom” – Ein Selbstbeurteilungsinstrument zur Früherkennung von psychischen Erkrankungen und Psychosen
  300. Psychotic Disorders and Menopause: The Untold Story
  301. Can Cortical Thickness Asymmetry Analysis Contribute to Detection of At-Risk Mental State and First-Episode Psychosis?: A Pilot Study
  302. Schizophrenia and Motherhood
  303. Treatment Options in Depression During the Postpartum
  304. Suizidversuche in der ersten und zweiten Generation der ImmigrantInnen aus der Türkei
  305. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis
  306. Elternschaft und Belastungserleben: Psychometrische Überprüfung des Parenting-Stress-Index (PSI) an einer deutschsprachigen Stichprobe
  307. Psychische Störungen in Zeiten hormoneller Umstellung bei Frauen – Eine selektive Übersicht
  308. STRATEGIES FOR IMPROVING THE PREDICTION OF PSYCHOSIS
  309. GRAY MATTER ABNORMALITIES AND COGNITIVE FUNCTION IN SUBJECTS AT RISK FOR PSYCHOSIS: LONGITUDINAL PERSPECTIVES
  310. CAN CORTICAL THICKNESS ANALYSIS IN AT RISK MENTAL STATE CONTRIBUTE TO EARLY DETECTION OF PSYCHOSIS?
  311. THE NEURAPRO (NORTH AMERICA, EUROPE, AUSTRALIA PRODROME) STUDY: A MULTICENTER RCT OF TREATMENT STRATEGIES FOR SYMPTOMATIC PATIENTS AT ULTRA-HIGH RISK FOR PROGRESSION TO SCHIZOPHRENIA AND RELATED DISORDERS. DESIGN AND STUDY PLAN
  312. Das Basel Screening Instrument für Psychosen (BSIP): Entwicklung, Aufbau, Reliabilität und Validität
  313. Insular pathology in the at-risk mental state
  314. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
  315. Nützen Behandlungsempfehlungen in psychiatrischen versicherungsrechtlichen Gutachten?
  316. Anterior and posterior cingulum abnormalities in the prodromal phase of schizophrenia
  317. 183 – The Basel Screening Instrument for Psychosis (BSIP) – predicitive validity and interrater reliability
  318. Anterior cingulate pathology in the prodromal stage of schizophrenia
  319. Geschlechtsspezifische Aspekte in der Psychotherapie
  320. Autorinnen und Autoren
  321. Screening Partnergewalt
  322. Neuropsychological deficits in individuals with an at risk mental state for psychosis — Working memory as a potential trait marker
  323. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
  324. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis
  325. The role of medication in suicide attempts in Switzerland
  326. Früherkennung schizophrener Psychosen bei Männern und Frauen
  327. Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis
  328. Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis
  329. Psychotic experiences in the general population: A twenty-year prospective community study
  330. Regional Gray Matter Volume Abnormalities in the At Risk Mental State
  331. Indication and impact of mentoring models
  332. Prospects for the classification of mental disorders in women
  333. Association of regional grey matter abnormalities with cognitive functions in the at risk mental state
  334. Cognitive capability of individuals at risk with and without transition to psychosis
  335. Akute Psychose
  336. Schizophrenie und verwandte Erkrankungen
  337. Akut- und Notfallpsychiatrie – Wo werden die Betroffenen behandelt?
  338. TC12C THE FEPSY (EARLY DETECTION OF PSYCHOSIS) STUDY – TRANSITION RATES AND PREDICTORS OF PSYCHOSIS
  339. 0352 FIRST SIGNS AND SYMPTOMS IN INDIVIDUALS AT RISK FOR PSYCHOSIS AND PATIENTS WITH A FIRST EPISODE OF PSYCHOSIS
  340. WC4G GREY MATTER ABNORMALITIES IN PEOPLE WITH AN AT RISK MENTAL STATE — CROSS-SECTIONAL AND LONGITUDINAL DATA
  341. Oestrogen-A Protective Factor in Schizophrenia?
  342. The Basel early‐detection‐of‐psychosis (FEPSY)‐study – design and preliminary results
  343. Radiological findings in individuals at high risk of psychosis
  344. Early detection and treatment of schizophrenia: how early?
  345. Postpartale Depression
  346. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
  347. Book review
  348. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia
  349. Buchbesprechung
  350. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
  351. Size of burden of schizophrenia and psychotic disorders
  352. Werden psychisch Kranke zu schnell in die Rente „abgeschoben”?
  353. Estrogen Effects in Psychiatric Disorders
  354. Group Psychotherapy for Depression in Early Stages of Motherhood
  355. Diagnostic Classification of Perinatal Mood Disorders
  356. Chronisch subdurales Hämatom bei einem Patienten mit Verdacht auf Prodromalstadium einer Schizophrenie
  357. Geschlechtersensible Betreuungsansätze
  358. Behandlungsprobleme bei schizophrenen Störungen
  359. Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?
  360. Postpartum depression: do we still need this diagnostic term?
  361. Gruppentherapie bei Depression in der frühen Mutterschaft
  362. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY)
  363. Östrogene und gonadale Achse Implikationen für die Therapie von Frauen mit Schizophrenien
  364. Oestrogens and schizophrenia
  365. Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain
  366. Oestrogens and schizophrenia - Introduction
  367. Oestrogen effects in schizophrenia and their potential therapeutic implications - Review
  368. Östrogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und Gynäkologie
  369. Estrogen effects in schizophrenia — brief update and potential therapeutic implications
  370. Group therapy for mothers with depression
  371. Sexualhormone und Psyche
  372. Innentitel
  373. 1 Einfluss von Östrogenen und Gestagenen auf das Zentralnervensystem
  374. 2 Das prämenstruelle Syndrom
  375. 5 Östrogene und schizophrene Psychosen
  376. 4 Hormonelle Aspekte bei affektiven Störungen, Angstund Zwangserkrankungen
  377. 6 Einfluss von Psychopharmaka auf Reproduktion und Kontrazeption
  378. 7 Sachverzeichnis
  379. Einführung: Sexualhormone und Psyche – Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption
  380. 3 Postpartale Depression und depressive Zustände im Klimakterium sowie unter der Hormonsubstitution
  381. Schizophrenie und Wahn im höheren und hohen Lebensalter
  382. Geschlechtsunterschiede bei Schizophrenie - m�gliche therapeutische Implikationen
  383. Gruppentherapie f�r depressive M�tter
  384. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry
  385. Book Reviews
  386. Psychische Erkrankungen bei Frauen - einige Argumente für eine geschlechtersensible Psychiatrie und Psychotherapie/ Mental diseases in women - some arguments for a gender-sensitive psychiatry and psychotherapy
  387. Association between oestradiol and puerperal psychosis
  388. Computer-assisted self-monitoring by patients with schizophrenia
  389. Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia
  390. Visual cognitive deficits in patients with borderline personality disorder
  391. The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective
  392. The ABC schizophrenia study: a preliminary overview of the results
  393. Gonadal function and its influence on psychopathology
  394. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle
  395. Causes and Consequences of the Gender Difference in Age at Onset of Schizophrenia
  396. What do we really know about late-onset schizophrenia?
  397. 50 Jahre nach Manfred Bleuler
  398. Psychische Störungen und Erkrankungen nach der Entbindung
  399. Changing patterns of mental health care in Germany
  400. Late onset schizophrenia — A valid entity? An empirical study on risk factors, psychopathology and course
  401. Case management for schizophrenic patients at risk for rehospitalization: A case control study
  402. Symptom Assessment in Casenotes and the Clinical Diagnosis of Schizophrenia
  403. Late-onset Schizophrenia and Late Paraphrenia
  404. Onset and Early Course of Schizophrenia
  405. Further evidence for a specific role of estradiol in schizophrenia?
  406. Validation of Danish case register diagnosis for schizophrenia
  407. Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany
  408. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia
  409. Organic factors and the clinical features of late paranoid psychosis: a comparison with Alzheimer's disease and normal ageing
  410. The Epidemiology of Early Schizophrenia
  411. Wirken Östrogene antipsychotisch?
  412. Can Estradiol Modulate Schizophrenic Symptomatology?
  413. Higher morbidity risk for schizophrenia in males: Fact or fiction?
  414. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia
  415. Schizophrenia and oestrogens — is there an association?
  416. Compulsory admission of psychiatric patients – an international comparison
  417. Einfluß des Menstruationszyklus auf die therapeutische Ansprechbarkeit schizophrener Patientinnen
  418. Schizophrenie — Eine Krankheit verliert ihre Dämonie
  419. The influence of age and sex on the onset and early course of schizophrenia
  420. Does case management reduce the rehospitalization rate?
  421. Die Zwangseinweisung psychiatrischer Patienten im nationalen und internationalen Vergleich - Häufigkeiten und Einflußfaktoren
  422. Is age of onset in schizophrenia influenced by marital status?
  423. First onset and early symptomatology of schizophrenia
  424. IRAOS: an instrument for the assessment of onset and early course of schizophrenia
  425. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle
  426. Effects of the Menstrual Cycle on the Therapeutic Response in Schizophrenia
  427. Effects of the menstrual cycle on therapeutic response in schizophrenic patients
  428. Interview "Onset of Schizophrenia"
  429. Geschlechtsunterschiede bei schizophrenen Erkrankungen
  430. Factors influencing compulsory admission of psychiatric patients
  431. Différences selon le sexe dans l’âge d’apparition, la symptomatologie et l’évolution de la schizophrénie
  432. 15 Jahre Psychiatriereform in der Bundesrepublik Deutschland
  433. Community care in child psychiatry
  434. Gender Differences in Age at Onset and Course of Schizophrenic Disorders
  435. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study
  436. Schizophrenia — a disease of young single males?
  437. Central Institute of Mental Health, Mannheim, West Germany
  438. Was ist postpartale Depression?
  439. Estrogens and Schizophrenia
  440. Early Detection of Psychosis - Helpful or Stigmatizing Experience for Those Concerned?
  441. Early Detection and Intervention in Psychosis
  442. Neurocognition and Motor Functioning in the Prediction of Psychosis